Comment Published 2026-10-19

Petter Segelman Lindqvist:Highest dose level in phase Ib initiated and phase II approaching

“The second quarter of 2026 was characterised by a continued strong focus on driving the clinical development of our drug candidate arfolitixorin forward towards becoming a new cornerstone in the treatment of cancer. During the quarter, we placed additional emphasis on optimising the study design and accelerating patient recruitment. With a newly opened trial centre in Germany in the third quarter, as well as approval from the safety committee to initiate the highest level in the dose escalation, 500 mg/m2, we are stepping up a gear as we advance towards the Phase II part of the study,” says Petter Segelman Lindqvist.

Comment by: Petter Segelman Lindqvist

Chief Executive Officer